On September 19, 2019 Benitec Biopharma Ltd (ASX: BLT,NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary DNA-directed RNA interference ("ddRNAi") platform, reported that Jerel A. Banks, M.D. Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the Ladenburg Thalmann 2019 Healthcare Conference (Press release, Benitec Biopharma, SEP 19, 2019, View Source [SID1234539651]). Relevant details as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date:

Tuesday, September 24, 2019

Event:

Ladenburg Thalmann 2019 Healthcare Conference

Location:

Sofitel, New York, NY

Time:

11:30 A.M. EST

A live webcast of the presentation will be streamed on the Investor Relations section of the Company’s website, View Source, and a copy of the presentation will be released to the ASX, Nasdaq, and posted on the Company’s website at the above URL prior to the event.